StockData
CVSIOTCPharmaceutical PreparationsFiscal year ends December 31

CV Sciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.01−0.00 (-21.13%)

Close on Oct 19, 2026

Market cap
$2.30M
P/E (TTM)
–
Dividend yield
–

About CV Sciences

Pharmaceutical Preparations, SIC 2834

CV Sciences, Inc. is a consumer wellness company that develops, manufactures, and markets herbal supplements, cannabidiol (CBD) products, and plant-based foods. Its offerings include hemp extracts, cannabinoid-free supplements, and shelf-stable plant-based protein foods marketed under brand names such as +PlusCBD, +PlusHLTH, Cultured Foods, and Lunar Fox. The company serves individual consumers, retailers, wholesalers, and pet owners, while also operating a business-to-business contract manufacturing service that provides custom softgel and tincture encapsulation for clients in the supplement and nutrition industry.

The company operates primary facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland, with its corporate headquarters located in San Diego. Its hemp-based products are distributed across North America through approximately 2,500 brick-and-mortar retail stores and e-commerce platforms. Its plant-based food products are primarily distributed across European retail markets through regional distributors and to select retailers in the United States.

Summary of the business section of CV Sciences's latest annual report, written by StockData.

Company profile

Company

Legal name
CV Sciences, Inc.
Founded
2010
Headquarters
San Diego, CA
Address
9530 Padgett Street, Suite 107 92126
Phone
(866) 290-2157
Employees
44, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
HASKELL & WHITE LLP, Irvine, California

Stock & identifiers

Ticker
CVSI
Exchange
OTC
Shares outstanding
226M, Aug 11, 2026
Public float
$7.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1510964
CUSIP
126654102
ISIN
US1266541028
LEI
549300CTTCLKOE31VK58
EIN
80-0944970

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Joseph D. DowlingChief Executive Officer, Director15,000
Joerg GrasserChief Financial Officer15,000
James Michael Corroon Jr.Director1,000
William McCorkleDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Mr. Dowling
$419.00K$423.10K$307.99K––
FY2024
Mr. Dowling
$457.67K$241.26K$343.32K$100–
FY2023
Mr. Dowling
$403.15K$313.97K$273.04K$133–
FY2022
Mr. Dowling
$298.98K$245.29K$210.47K$25–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had a total of 44 employees, which included 36 full-time and 1 part-time employee in the U.S.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 1, 2022Late filingNotification of late filing
Dec 1, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 30, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 16, 2020Late filingNotification of late filing
Apr 15, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 24, 2017Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 29, 2016Late filingNotification of late filing
Jan 4, 2016Name changeName changed from CannaVEST Corp. to CV Sciences, Inc.
Jan 4, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 20, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 19, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 16, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 20, 2013Auditor changeChange in certifying accountant (8-K Item 4.01)
May 15, 2013Late filingNotification of late filing
May 14, 2013Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 1, 2013Late filingNotification of late filing
Mar 8, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 30, 2012Name changeName changed from Foreclosure Solutions, Inc. to CannaVEST Corp.
Mar 30, 2012Late filingNotification of late filing